A. Oaknin

Statistics

Publications

Citations

H-Index

Active since

2019

Affiliations

Vall d'Hebron Hospital Universitari(Current)

A. Oaknin is an author at Vall d'Hebron Hospital Universitari specializing in ovarian cancer chemotherapy, ovarian cancer treatment, and chemotherapy.

Publications per year

2019–2022

Publications

LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)

J.E. Kurtz, E. Pujade-Lauraine, A. Oaknin et al. · Annals of Oncology · 2022 · 15 citations

Medicine, Oncology, Pharmacology +17

VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)

Robert L. Coleman, Gini F. Fleming, Mark F. Brady et al. · Annals of Oncology · 2019 · 10 citations · Full text

Medicine, Gynecology, Oncology +13

1–2 of 2